Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA - Italian Multiple Myeloma Network

Journal of Clinical Oncology

Volumn 25, Issue 28, 2007, Pages 4459-4465

  Palumbo, Antonio ^a   Falco, Patrizia ^b   Corradini, Paolo ^b   Falcone, Antonietta ^b   Di Raimondo, Francesco ^b   Giuliani, Nicola ^b   Crippa, Claudia ^b   Ciccone, Giovannino ^b   Omedè, Paola ^b   Ambrosini, Maria Teresa ^b   Gay, Francesca ^b   Bringhen, Sara ^b   Musto, Pellegrino ^b   Foà, Robin ^b   Knight, Robert ^b   Zeldis, Jerome B ^b   Boccadoro, Mario ^b   Petrucci, Maria Teresa ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LENALIDOMIDE; MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE;

ADULT; AGED; ANALYTIC METHOD; ANEMIA; ANOREXIA; ARTICLE; CANCER DIAGNOSIS; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOOD DISORDER; MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOXICITY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SURVIVAL;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 35348923502     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.3463     Document Type: Article

References (37)

1. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488, 2005
2. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan and prednisone as treatment of multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832-3842, 1998
3. Boccadoro M, Marmont F, Tribalto M, et al: Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 9:444-448, 1991
4. Cavo M, Benni M, Ronconi S, et al: Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: Final analysis of a randomized clinical study. Haematologica 87:934-942, 2002
5. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
6. Child JA, Morgan GJ, Davies FE, et al: Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003
7. Palumbo A, Bringhen S, Petrucci MT, et al: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 104:3052-3057, 2004
8. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
9. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
10. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
11. Dimopoulos MA, Spencer A, Attal M, et al: Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010). Blood 106:230a, 2005 (abstr 6)
12. Weber D, Chen C, Niesvizky R, et al: Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009). J Clin Oncol 24:427s, 2006 (suppl; abstr 7521)
13. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831, 2006
14. Rajkumar SV, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053, 2005
15. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
16. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional chemotherapy. Blood 96:2943-2950, 2000
17. Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216, 2001
18. Gupta D, Treon SP, Shima Y, et al: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 15:1950-1961, 2001
19. Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivative as anticancer agents. Nat Rev Cancer 4:314-322, 2004
20. Hideshima T, Richardson PG, Anderson KC: Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Investig Drugs 15:171-179, 2006
21. Knight R, DeLap RJ, Zeldis JB: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079-2080, 2006
22. Rajkumar SV, Blood E: Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 354:2079-2080, 2006
23. Zonder JA, Barlogie B, Durie BG, et al: Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis. Blood 108:403, 2006
24. Facon T, Mary J, Harousseau J, et al: Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed multiple myeloma. J Clin Oncol 24:1s, 2006 (suppl; abstr 1)
25. Mateos MV, Hernandez JM, Hernandez MT, et al: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 108:2165-2172, 2006
26. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102:1115-1123, 1998
27. Cancer Therapy Evaluation Program: Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. http://ctep.cancer.gov
28. Ahmann GJ, Jalal SM, Juneau AL, et al: A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gamopathies. Cancer Genet Cytogenet 101:7-11, 1998
29. Fonseca R, Barlogie B, Bataille R, et al: Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 64:1546-1558, 2004
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Facon T, Mary JY, Pegourie B, et al: Dexamethasone-based regimens versus melphalanprednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 107:1292-1298, 2006
32. Orlowski RZ: Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation. Am Soc Hematol Educ Program 338-347, 2006
33. Jaksic W, Trudel S, Chang H, et al: Clinical outcomes in t(4;14) multiple myeloma: A chemotherapysensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 23:7069-7073, 2005
34. Chng WJ, Santana-Davila R, Van Wier SA, et al: Prognostic factors for hyperdiploid-myeloma: Effects of chromosome 13 deletions and IgH translocations. Leukemia 20:807-813, 2006
35. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030, 2006
36. Rajkumar SV, Dispenzieri A: Evaluation and monitoring of response to therapy in multiple myeloma. Haematologica 90:1305-1308, 2005
37. Attal M, Harousseau JL, Facon T, et al: For the Intergroupe Francophone du Myelome: Single versus double autologous transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003